Advancements in the Treatment of Desmoid Tumors : Episode 11
DeFi: Nirogacestat in Patients with Progressing Desmoid Tumors
Jonathan Trent, MD, PhD, discusses the rationale and design of the DeFi study, instrumental in the FDA approval of nirogacestat, and explores key efficacy and safety findings from this research.
EP: 1.An Overview of the Landscape Surrounding Desmoid Tumors
EP: 2.Expert Perspectives on the Pathogenesis and Diagnosis of Desmoid Tumors
EP: 3.Signs and Symptoms of Desmoid Tumors and Their Impact on Quality of Life
EP: 4.Active Surveillance in Frontline Management of Desmoid Tumors
EP: 5.The Evolving Role of Surgery in the Management of Desmoid Tumors
EP: 6.Treatment Strategies Using Radiotherapy or Other Locoregional Approaches in Desmoid Tumors
EP: 7.Approaches to Systemic Therapy in Desmoid Tumors: The Role of Chemotherapy
EP: 8.The Role of Supportive Care Measures in Patients with Desmoid Tumors
EP: 9.Desmoid Tumors in Women: Special Considerations for Pregnancy and Contraception
EP: 10.Targeting NOTCH Pathway Signaling with Nirogacestat
Now Viewing
EP: 11.DeFi: Nirogacestat in Patients with Progressing Desmoid Tumors
EP: 12.Impact of Nirogacestat on Pain, Quality of Life, and Fertility in Patients with Desmoid Tumors
EP: 13.Nirogacestat's Impact on the Future Treatment of Desmoid Tumors
EP: 14.Future Perspectives on the Treatment of Desmoid Tumors
Related Videos
